How to Identify Treatment-Resistant Depression in Medication-Treated MDD
How can clinicians operationally identify treatment-resistant depression in adults receiving medication treatment for major depressive disorder?
When a patient with major depressive disorder continues through multiple antidepressant regimens, clinicians need a consistent way to determine when the course meets a treatment-resistant pattern. This guide applies to adults with medication-treated MDD and summarizes the article's commonly used treatment-pattern definition of TRD.
-
Confirm medication-treated MDD
Start with an adult patient who has major depressive disorder and is receiving antidepressant treatment. In the study's source claims analyses, MDD was identified from ICD-9-CM or ICD-10-CM diagnosis codes in medical claims, and the population of interest was adults with medication-treated MDD.
-
Verify 2 antidepressant courses of adequate dose and duration
Review the treatment history to determine whether the patient has already undergone 2 antidepressant treatment courses that were considered of adequate dose and duration. The article does not specify the exact adequacy thresholds in this paper, but TRD classification required that 2 such courses had been changed before moving on to the next step.
-
Identify initiation of a third treatment course
Classify the patient as having TRD when a third antidepressant treatment course is initiated after the 2 prior adequate courses have been changed. The study explicitly counted augmentation therapy within this third treatment course definition.
-
Allow limited gaps between consecutive courses
When reconstructing the sequence of treatment courses, allow a treatment gap of up to 180 days between consecutive antidepressant courses. Gaps longer than this fall outside the article's operational definition used to identify TRD.
-
Classify non-TRD MDD if criteria are not met within 2 years
If an adult with MDD and antidepressant treatment does not meet the above TRD criteria within 2 years of the first antidepressant claim, classify the episode as non-TRD MDD under the study framework. This creates a time-bounded distinction between treatment-resistant and non-treatment-resistant medication-treated MDD.
Clinical Considerations
- The article notes that no universally accepted definition of TRD exists, so this is one commonly used operational definition rather than a definitive clinical standard.
- The source studies used proxy definitions based on treatment patterns because symptom burden was not available in the claims databases.
- The guide reflects an adult, claims-based framework derived from insured populations across major US payer types and may not capture all clinically relevant presentations.
- The paper includes augmentation therapy in the third treatment course definition, but it does not provide a detailed symptom-based protocol for assessing nonresponse or remission.
Bottom Line
In this article, TRD is operationally identified when an adult with medication-treated MDD starts a third antidepressant treatment course, including augmentation, after 2 antidepressant courses of adequate dose and duration, with gaps of no more than 180 days between courses.
